

Survey of Clinical Proteomic Tumor Analysis Consortium (CPTAC, Phase II)

Survey of NCI Proteomics News Listserv Recipients

The National Cancer Institute (NCI) launched the Clinical Proteomic Technologies for Cancer (CPTC) initiative in 2006 (Phase I) to specifically address barriers in proteomics research to ensure any findings are due to the biology and not analytical variability. Building upon the accomplishments of CPTC Phase I, the Clinical Proteomic Tumor Analysis Consortium (CPTAC) program (Phase II) was launched in August 2011 to apply the analytical workflows developed in Phase I to better understand cancer biology. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. CPTAC has developed a range of products, including antibodies and a centralized data repository for the dissemination of proteomic data to the public.

NCI has retained Westat, an independent research organization, to conduct a survey of CPTAC (Phase II) that will provide information on the degree to which CPTAC is meeting its goals and identify opportunities for program improvement. The views of individuals who receive emails via NCI's Proteomics News listserv are critical to understanding and improving the efforts of CPTAC. Participation in this survey is voluntary, but your views are important and we hope you will complete it even if you know little about CPTAC. All data will be reported to NCI in aggregate form. No reports will contain findings linked to individual respondents or institutions.


If you have questions about this survey, please contact Dr. Eden Segal at edensegal@westat.com or 240-314-7583. If you have questions about your rights and welfare as a research participant, please call the Westat Human Subjects Protections office at 1-888-920-7631. Please leave a message with your full name, the name of this study—CPTAC Survey for NIH—and a phone number beginning with the area code. Someone will return your call as soon as possible. If you have questions about the CPTAC program itself, contact Dr. Tara Hiltke at hiltket@mail.nih.gov or 301-451-8511.

OMB No.: 0925-0642; Expiration Date: 09/30/2014


Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0048). Do not return the completed form to this address.


If you agree to participate in this short survey click Next, below.


Next





[Q3 Not at all familiar skips to survey Page 7]











Display a "Thank You" Page?

No, do not display a thank y	ou page. After f	finishing the survey,	respondents will	proceed directly	y to the completion	n option you s	pecify
below.							

0	Yes.	displa	y a thank	you page	after finishing	the survey	L
---	------	--------	-----------	----------	-----------------	------------	---

Thank	you	very	much	for	your	participation.	